111 results on '"LARYNGEAL tumors"'
Search Results
2. Risk factors and healing factors for pharyngocutaneous fistula after total laryngectomy for laryngeal cancer: An epidemiological study.
- Author
-
Tai, Yong, Zang, Yanzi, Liu, Tongxun, Ma, Jiqing, Qin, Litao, Ji, Yuzi, Dai, Hanqing, Wang, Guangke, Ma, Lingcao, and Liu, Fei
- Subjects
WOUND healing ,RISK assessment ,FISTULA ,STATISTICAL significance ,RESEARCH funding ,LARYNGEAL tumors ,MULTIPLE regression analysis ,SMOKING ,HEMOGLOBINS ,RETROSPECTIVE studies ,MULTIVARIATE analysis ,DESCRIPTIVE statistics ,PHARYNGEAL diseases ,SURGICAL complications ,CANCER chemotherapy ,LARYNGECTOMY ,ONE-way analysis of variance ,ALBUMINS ,DATA analysis software ,EPIDEMIOLOGICAL research ,C-reactive protein ,DISEASE risk factors - Abstract
To analyse the risk factors and healing factors of pharyngocutaneous fistula (PCF) in patients with laryngeal cancer after total laryngectomy, and to explore the relevant epidemiology. A retrospective analysis was conducted on laryngeal cancer patients who underwent total laryngectomy in our hospital from January 2010 to December 2022. The 349 patients included in the study were divided into a PCF group of 79 and a non‐PCF group of 270. Perform one‐way analysis of variance and multivariate logistic analysis on various data of patients included in the statistics, and analyse the risk factors and healing factors of PCF. Smoking, history of radiation therapy for laryngeal cancer, history of chemotherapy for laryngeal cancer, tumour location (larynx, pharynx, oesophagus), preoperative albumin, postoperative proteinaemia, <99 haemoglobin, postoperative haemoglobin, postoperative C‐reactive protein (CRP) level are the risk factors for PCF. Also, radiation therapy and postoperative proteinaemia were the main reasons for preventing PCF healing. Smoking history, laryngeal cancer, radiation therapy, albumin, haemoglobin and CRP are risk factors for postoperative PCF after total laryngectomy, while radiation therapy and postoperative hypoalbuminaemia are key factors affecting PCF healing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. EXPLORING THE UNCHARTED: A CASE SERIES OF RARE HEAD AND NECK SOFT TISSUE NEOPLASM.
- Author
-
Babu, Agil, Patel, Pinakin, Lakhera, Kamal Kishor, Mehta, Deeksha, Singh, Suresh, and Mohan, Pranav
- Subjects
HEAD & neck cancer diagnosis ,LEIOMYOSARCOMA ,BIOPSY ,SURGICAL flaps ,TONSIL cancer ,TONGUE tumors ,CANCER chemotherapy ,RHABDOMYOSARCOMA ,RETROSPECTIVE studies ,ACQUISITION of data ,MASSETER muscle ,LARYNGEAL tumors ,CANCER relapse ,SOFT tissue tumors ,TUMOR classification ,TREATMENT effectiveness ,CASE studies ,MEDICAL records ,CELLS ,LARYNGOSCOPY ,COMPUTED tomography ,RADIOTHERAPY ,NASAL tumors ,RARE diseases ,MAXILLARY tumors ,CONNECTIVE tissue tumors ,GLOSSECTOMY ,VINCRISTINE - Published
- 2024
4. Factors Associated with Total Laryngectomy Utilization in Patients with cT4a Laryngeal Cancer.
- Author
-
Ritter, Alex R., Yildiz, Vedat O., Koirala, Nischal, Baliga, Sujith, Gogineni, Emile, Konieczkowski, David J., Grecula, John, Blakaj, Dukagjin M., Jhawar, Sachin R., VanKoevering, Kyle K., and Mitchell, Darrion
- Subjects
- *
LARYNGECTOMY , *LOG-rank test , *MULTIVARIATE analysis , *CANCER chemotherapy , *RETROSPECTIVE studies , *ACQUISITION of data , *DISEASES , *COMPARATIVE studies , *MEDICAL records , *RESEARCH funding , *PHYSICIAN practice patterns , *LOGISTIC regression analysis , *ODDS ratio , *MEDICAID , *LONGITUDINAL method , *PROPORTIONAL hazards models , *OVERALL survival ,LARYNGEAL tumors - Abstract
Simple Summary: Total laryngectomy (TL) with post-operative radiotherapy (PORT) is recommended for patients with clinically advanced (cT4a) laryngeal cancer and is associated with superior outcomes compared to non-operative treatment with chemoradiation. Despite this, many patients with a diagnosis of laryngeal cancer do not receive TL as part of their treatment course, which places them at risk for inferior oncologic outcomes, and the factors associated with the utilization of TL in this setting remain poorly understood. Thus, the aims of this observational cohort study utilizing the National Cancer Database (NCDB) were both to elucidate the patient and treatment facility characteristics associated with TL utilization in patients with cT4a laryngeal cancer and to evaluate how its usage has changes over time. Background: Despite recommendations for upfront total laryngectomy (TL), many patients with cT4a laryngeal cancer (LC) instead undergo definitive chemoradiation, which is associated with inferior survival. Sociodemographic and oncologic characteristics associated with TL utilization in this population are understudied. Methods: This retrospective cohort study utilized hospital registry data from the National Cancer Database to analyze patients diagnosed with cT4a LC from 2004 to 2017. Patients were stratified by receipt of TL, and patient and facility characteristics were compared between the two groups. Logistic regression analyses and Cox proportional hazards methodology were performed to determine variables associated with receipt of TL and with overall survival (OS), respectively. OS was estimated using the Kaplan–Meier method and compared between treatment groups using log-rank testing. TL usage over time was assessed. Results: There were 11,149 patients identified. TL utilization increased from 36% in 2004 to 55% in 2017. Treatment at an academic/research program (OR 3.06) or integrated network cancer program (OR 1.50), male sex (OR 1.19), and Medicaid insurance (OR 1.31) were associated with increased likelihood of undergoing TL on multivariate analysis (MVA), whereas age > 61 (OR 0.81), Charlson–Deyo comorbidity score ≥ 3 (OR 0.74), and clinically positive regional nodes (OR 0.78 [cN1], OR 0.67 [cN2], OR 0.21 [cN3]) were associated with decreased likelihood. Those undergoing TL with post-operative radiotherapy (+/− chemotherapy) had better survival than those receiving chemoradiation (median OS 121 vs. 97 months; p = 0.003), and TL + PORT was associated with lower risk of death compared to chemoradiation on MVA (HR 0.72; p = 0.024). Conclusions: Usage of TL for cT4a LC is increasing over time but remains below 60%. Patients seeking care at academic/research centers are significantly more likely to undergo TL, highlighting the importance of decreasing barriers to accessing these centers. Increased focus should be placed on understanding and addressing the additional patient-, physician-, and system-level factors that lead to decreased utilization of surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. The Histological Background of Recurrence in Laryngeal Squamous Cell Carcinoma: An Insight into the Modifications of Tumor Microenvironment.
- Author
-
Arcovito, Giorgia, Palomba, Annarita, Gallo, Oreste, and Franchi, Alessandro
- Subjects
- *
IMMUNE checkpoint inhibitors , *PROGRAMMED death-ligand 1 , *CANCER chemotherapy , *CANCER relapse , *IMMUNOSUPPRESSION , *RADIOTHERAPY , *T cells , *SQUAMOUS cell carcinoma ,LARYNGEAL tumors - Abstract
Simple Summary: Laryngeal cancer is a relatively common neoplasm of head and neck, whose management hinges on a combination of treatments such as surgery, radiotherapy and chemotherapy. Tumor recurrences may present important differences from the primary tumor that largely depend on previous treatments. the immune system plays a crucial role in the natural course of the disease, owing the capability to influence its behavior through a complex interaction of mechanisms. For this reason, the use of immunotherapy in addition to standard therapies is increasingly gaining importance nowadays and the selection of patients who can benefit the most from this treatment can help optimizing its success. However, conventional treatments can induce relevant changes in the host immune response, thus affecting tumor progression and patient outcome. This fact should be taken into account when planning immune-based treatments like immune checkpoint inhibitors. In this article, we review the histologic and molecular treatment-induced changes that may affect the diagnosis of recurrent laryngeal cancer, the assessment of predictive markers, and the response to treatment with immune checkpoint inhibitors. Recurrent laryngeal carcinoma presents differences from the primary tumor that largely depend on the treatment. In this article, we review the histologic and molecular treatment-induced changes that may affect the diagnosis of recurrent laryngeal carcinoma, the assessment of predictive markers, and the response to treatment with immune checkpoint inhibitors. Radiotherapy induces profound modifications that are strictly related to necrosis of different tissue components, fibrosis, and damage of the tumor vessels. Postradiotherapy recurrent/persistent laryngeal squamous cell carcinoma typically presents a discohesive growth pattern within a fibrotic background associated with significant changes of the tumor immune microenvironment, with both important immunosuppressive and immunostimulatory effects. Overall, the increase of immunoregulatory cells and immune checkpoints such as CTLA-4, TIM-3, PD-1, and PD-L1 induced by radiotherapy and chemotherapy strongly supports the use of immune checkpoint inhibitors in recurrent/persistent laryngeal carcinoma. Future studies aiming to identify predictive factors of the response to immune checkpoint inhibitors should consider such treatment-induced modifications. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Non-surgical organ preservation in laryngeal and hypopharyngeal cancers: an audit from the clinic.
- Author
-
Sood, S, Sinha, S, Balaji, A, Mundhe, S R, Mummudi, N, Budrukkar, A, Swain, M, Prabash, K, Noronha, V, Joshi, A, Patil, V, and Laskar, S G
- Subjects
- *
LARYNX , *DISEASE progression , *CANCER chemotherapy , *RETROSPECTIVE studies , *PRESERVATION of organs, tissues, etc. , *CANCER patients , *COMPARATIVE studies , *HYPOPHARYNX , *DESCRIPTIVE statistics , *QUALITY of life , *PROGRESSION-free survival , *RADIOTHERAPY , *HYPOPHARYNGEAL cancer , *SQUAMOUS cell carcinoma , *OVERALL survival ,LARYNGEAL tumors - Abstract
Background: There is increasing concern regarding efficacy of organ preservation protocol in laryngeal and hypopharyngeal cancers. Method: This study retrospectively assessed disease-related and functional outcomes of 191 patients with non-metastatic laryngeal or hypopharyngeal squamous cell carcinoma treated with curative intent (radiotherapy with or without chemotherapy). Results: Seventy-six patients (39.8 per cent) had a primary cancer in the larynx, and 115 patients (60.2 per cent) had a primary cancer in the hypopharynx. The median follow up was 39 months. The 3-year time to progression, overall survival, local control and laryngectomy free survival was 56.2 per cent, 76.3 per cent, 73.2 per cent and 67.2 per cent, respectively. At the time of analysis, 83 patients (43.5 per cent) were alive and disease free at their last follow up and did not require tube feeding or tracheostomy. The laryngo-oesophageal dysfunction-free survival was 61 per cent at 3 years. Conclusion: Organ conservation protocols remain the standard of treatment in appropriately selected patients with laryngeal and hypopharyngeal cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Image-guidance triggered adaptive radiation therapy in head and neck squamous cell carcinoma: single-institution experience and implications for clinical practice.
- Author
-
Gupta, Tejpal, Maheshwari, Guncha, Joshi, Kishore, Sawant, Priya, Mishra, Ajay, Khairnar, Sunil, Patel, Prapti, Sinha, Shwetabh, Swain, Monali, Budrukkar, Ashwini, Ghosh-Laskar, Sarbani, and Agarwal, Jai-Prakash
- Subjects
CANCER chemotherapy ,HEAD & neck cancer ,RETROSPECTIVE studies ,ACQUISITION of data ,LARYNGEAL tumors ,OROPHARYNGEAL cancer ,CANCER patients ,COMPARATIVE studies ,RADIATION doses ,SYMPTOMS ,WEIGHT loss ,MEDICAL records ,CHI-squared test ,DESCRIPTIVE statistics ,RADIOTHERAPY ,SQUAMOUS cell carcinoma ,HYPOPHARYNGEAL cancer ,RADIATION dosimetry - Abstract
Copyright of Journal of Medical Imaging & Radiation Sciences is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
8. Cytotoxic effects of water and ethanolic extracts of Turkish propolis on human laryngeal epidermoid carcinoma cell lines.
- Author
-
KULAKSIZ, Betül DEĞER, İMAMOĞLU, Mehmet, DEĞER, Orhan, ÇAKIROĞLU, Kübra AKBULUT, DEMİR, Selim, and SÖNMEZ, Mehmet
- Subjects
DNA ,CANCER chemotherapy ,WATER ,LARYNGEAL tumors ,PROPOLIS ,CELL proliferation ,RESEARCH funding ,CELL lines ,PLANT extracts ,ETHANOL - Abstract
Propolis is a natural resinous substance collected by bees from various types of trees and plants and has antibacterial, antiviral and antitumoral features depending on its antioxidant properties. Major aim is to investigate cytotoxic effect of Turkish propolis on human laryngeal epidermoid carcinoma (HEp-2) cells. HEp-2 cells/well were loaded on RTCA(real time cell analysis) system and the cell index was followed up during 48 hours. Water extract of Turkish propolis (WEP) of 250-10.000 μg/mL concentrations and ethanolic extracts of Turkish propolis (EEP) of 10-2.400 μg/mL concentrations were treated with HEp-2 cells and followed by RTCA system. The cell indexes and IC50 values were determined. HEp-2 cells were incubated with WEP and EEP. Proliferation was followed by flow cytometric DNA cycle analysis. WEP and EEP were found to be cytotoxic to HEp-2 cells. When WEP and EEP were incubated with HEp-2 cells during 72 hours, the highest antiproliferative effect was seen by interfering DNA cycles. Turkish propolis extracts were found to be cytotoxic and antiproliferative to HEp- 2 cells in the present study, therefore, it was concluded that it may fall within chemotherapy or target therapies for larynx cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Trends in Cancer Treatment for Oral Cavity, Oropharynx, and Larynx in 2016 Versus 2009: SEER Patterns of Care Studies.
- Author
-
Weeks, Kristin S., Lynch, Charles F., and Pagedar, Nitin
- Subjects
- *
MOUTH tumors , *CARBOPLATIN , *CANCER chemotherapy , *OROPHARYNGEAL cancer , *CISPLATIN , *CHI-squared test , *RADIOTHERAPY , *LOGISTIC regression analysis ,LARYNGEAL tumors - Abstract
Purpose: To determine if there was a higher percentage of patients treated surgically and with advanced radiotherapy in 2016 (N = 897) versus 2009 (N = 1136), the patient and tumor characteristics associated with surgical care and advanced radiotherapy, and if chemotherapy or targeted agent use varied over time for squamous cell carcinoma of the head and neck. Methods: We utilized Surveillance Epidemiology and End Results Patterns of Care datasets. Rao-Scott Chi-square tests and logistic regressions were applied to determine differences in surgery, advanced radiotherapy (RT), and chemotherapy by year. Results: There was a lower prevalence of surgery only treatment in 2016 versus 2009 with exception of oral cavity stages IVB/IVC and unknown, and larynx stage unknown. Advanced RT was more common in 2016 for patients receiving definitive RT among all sites, excluding stages I/II glottic larynx. Among each site (oral cavity, oropharynx, and larynx) lower stage was associated with increased odds of surgery. Among each site, advanced RT was more common in patients receiving definitive versus postoperative RT. For the larynx site, 2016 versus 2009 was associated with greater odds of advanced RT. Systemic treatment with fluorouracil, taxanes, or cetuximab was less prevalent in 2016. Conclusion: In 2016 versus 2009, there was largely not a higher percentage of patients treated surgically. There was a higher prevalence of advanced RT for definitive care. Further investigations of these patterns are needed, including trend analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma.
- Author
-
Linxweiler, Maximilian, Kühn, Jan Philipp, Neubert, Christian, Khreish, Fadi, Balensiefer, Benedikt, Wagner, Mathias, and Schick, Bernhard
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *ADENOCARCINOMA , *LUNG cancer , *IMMUNE checkpoint inhibitors , *CANCER chemotherapy , *METASTASIS , *TREATMENT effectiveness , *POSITRON emission tomography , *NECK , *COMPUTED tomography , *IMMUNOTHERAPY , *DISEASE remission ,LARYNGEAL tumors ,MEDIASTINAL tumors - Abstract
Background: Anti-PD1-Checkpoint inhibition (CI) is an established treatment of recurrent and/or metastatic head and neck cancer. A potential benefit from CI in early-stage disease that is usually treated by radiation or surgery has not been investigated so far and is currently not addressed in clinical trials. Case presentation: A 58-year-old man was diagnosed with a cT2 supraglottic laryngeal cancer and a synchronous metastasized adenocarcinoma of the lung. As the patient refused any treatment of his laryngeal cancer, he received combined immune-chemotherapy according to the KEYNOTE-189 protocol. After 4 cycles of pembrolizumab/carboplatin/pemetrexed, the patient showed a complete remission of his laryngeal cancer with a clear shrinkage of the mediastinal and hilar lung cancer metastases. After 21 cycles of maintenance therapy, the lung adenocarcinoma shows a stable disease status with no signs of any residual or recurrent laryngeal cancer. Conclusions: Anti-PD1-CI may be a treatment option also for early-stage HNSCC with excellent functional outcome when established therapies are not available. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Intra-arterial chemotherapy targeting metastatic cervical lymph nodes in head and neck cancer.
- Author
-
Murono, Shigeyuki, Komori, Takeshi, Endo, Kazuhira, Kondo, Satoru, Wakisaka, Naohiro, and Yoshizaki, Tomokazu
- Subjects
- *
HEAD tumors , *BLOOD vessels , *CANCER chemotherapy , *LYMPH nodes , *RETROSPECTIVE studies , *MANN Whitney U Test , *METASTASIS , *CHEMORADIOTHERAPY , *DESCRIPTIVE statistics , *COMPUTED tomography , *NECK tumors , *INTRA-arterial infusions ,LARYNGEAL tumors - Abstract
Large cervical lymph nodes and the extranodal extension of metastatic lymph nodes are considered poor prognostic factors in head and neck squamous cell carcinoma (HNC). The efficacy of intra-arterial chemotherapy (iaCT) targeting lymph node (LN) in HNC was examined. We performed a retrospective review of 41 patients with laryngeal and hypopharyngeal cancer showing metastatic cervical LN larger than 20 mm treated with iaCT with concurrent radiotherapy. The administration of cisplatin into LN was divided into three groups: no administration (NO), via the same artery as that supplying the primary tumor (SAME), and via a different artery from that supplying the primary tumor (DIFFERENT). A trend toward a more favorable three-year regional control in DIFFERENT compared to NO was observed, although the mean size of LN in DIFFERENT was larger than in the other groups. A better regional control was obtained in both DIFFERENT (p <.05) and DIFFERENT + SAME (p <.05) when overall rather than partial enhancement of lymph node by CT angiography was observed. Extranodal extension could be a factor predicting unfavorable regional control. Targeting lymph node may be helpful to avoid neck dissection when iaCT was planned in HNC with relatively large LNs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Laryngeal Myofibroblastic Tumor: A New Therapeutic Approach. A Case Report.
- Author
-
Gómez-Hervás, Javier, Moreno-Romera, Manuel, Arias, Fabio Hugo Escobar, and Gálvez, Esteban Merino
- Subjects
- *
CANCER chemotherapy , *MUSCLE cells , *ADRENOCORTICAL hormones , *INTRAVENOUS therapy , *ORAL drug administration , *DISEASES , *DISEASE remission ,LARYNGEAL tumors - Abstract
Myofibroblastic tumors are rare lesions which can affect any part of the body. Although benign, their mass effect causes symptoms that can become life-threatening. Supraglottic laryngeal involvement is extremely rare, with only 4 cases described in the English literature. Because the pathophysiology is unknown and the incidence is so low, there is no standardized therapeutic management, although for laryngeal tumors surgery has traditionally been the preferred initial option. Another less common option is intravenous and oral corticosteroid therapy, but this is usually reserved for myofibroblastic tumors in other head and neck sites that are more difficult to access surgically, or patients who cannot undergo surgery. These lesions have a very high tendency to recur, and morbidity rates are therefore also high. We present a case of supraglottic myofibroblastic tumor in which we elected high-dose corticosteroid therapy as the only form of treatment. With this new therapeutic approach, we avoided the undesirable effects of the usual type of surgery. At the 12-month follow-up, the patient is in complete remission. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.
- Author
-
Nutting, Christopher M., Griffin, Clare L., Sanghera, Paul, Foran, Bernadette, Beasley, Matthew, Bernstein, David, Cosgrove, Vivian, Fisher, Shelia, West, Catherine M., Sibtain, Amen, Palaniappan, Nachi, Urbano, Teresa Guerrero, Sen, Mehmet, Soe, Win, Rizwanullah, Mohammed, Wood, Katie, Ramkumar, Shanmugasundaram, Junor, Elizabeth, Cook, Audrey, and Roques, Tom
- Subjects
- *
DISEASE progression , *CONFIDENCE intervals , *CANCER chemotherapy , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *CANCER patients , *RADIATION doses , *DESCRIPTIVE statistics , *RADIOTHERAPY , *STATISTICAL sampling , *HYPOPHARYNGEAL cancer , *ALGORITHMS , *EVALUATION ,LARYNGEAL tumors - Abstract
Radical (chemo)radiotherapy offers potentially curative treatment for patients with locally advanced laryngeal or hypopharyngeal cancer. We aimed to show that dose-escalated intensity-modulated radiotherapy (DE-IMRT) improved locoregional control. We performed a phase III open-label randomised controlled trial in patients with laryngeal or hypopharyngeal cancer (AJCC III-IVa/b, TNM 7). Patients were randomised (1:1) to DE-IMRT or standard dose IMRT (ST-IMRT) using a minimisation algorithm, balancing for centre, tumour site, nodal status and chemotherapy use. DE-IMRT was 67.2 gray (Gy) in 28 fractions (f) to the primary tumour and 56Gy/28f to at-risk nodes; ST-IMRT was 65Gy/30f to primary tumour and 54Gy/30f to at-risk nodes. Suitable patients received 2 cycles of concomitant cisplatin and up to 3 cycles of platinum-based induction chemotherapy. The primary end-point was time to locoregional failure analysed by intention-to-treat analysis using competing risk methodology. Between February 2011 and October 2015, 276 patients (138 ST-IMRT; 138 DE-IMRT) were randomised. A preplanned interim futility analysis met the criterion for early closure. After a median follow-up of 47.9 months (interquartile range 37.5–60.5), there were locoregional failures in 38 of 138 (27.5%) ST-IMRT patients and 42 of 138 (30.4%) DE-IMRT patients; an adjusted subhazard ratio of 1.16 (95% confidence interval: 0.74–1.83, p = 0.519) indicated no evidence of benefit with DE-IMRT. Acute grade 2 pharyngeal mucositis was reported more frequently with DE-IMRT than with ST-IMRT (42% vs. 32%). No differences in grade ≥3 acute or late toxicity rates were seen. DE-IMRT did not improve locoregional control in patients with laryngeal or hypopharyngeal cancer. The trial is registered: ISRCTN01483375. • This phase III RCT does not support dose escalation using accelerated hypofractionation. • No benefit in local tumour control or survival was seen. • Two-year local tumour failure rate was approximately 30% in both treatment groups. • The larynx was preserved in about 90% patients in both treatment groups. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Laryngeal Synovial Sarcoma: A Systematic Review of the Last 40 Years of Reported Cases.
- Author
-
Shein, Gregory, Sandhu, Gurfateh, Potter, Alison, Loo, Christine, Jacobson, Ian, and Anazodo, Antoinette
- Subjects
- *
CANCER chemotherapy , *CANCER relapse , *COMBINED modality therapy , *MEDICAL information storage & retrieval systems , *LARYNGECTOMY , *MEDLINE , *RADIOTHERAPY , *RARE diseases , *SARCOMA , *SYSTEMATIC reviews , *TREATMENT effectiveness , *IFOSFAMIDE ,LARYNGEAL tumors - Abstract
Primary laryngeal synovial sarcoma is an extremely rare tumor predominantly affecting young adults. There are currently no well-defined guidelines to direct investigation and management, and treatment is largely based on what is known for synovial sarcoma of the upper and lower limbs. This PROSPERO-registered study aims to review the diagnostic methods, treatment regimens, and survival outcomes for patients with synovial sarcoma of the larynx. A systematic search of databases Medline, Embase, SCOPUS, and Web of Science was undertaken in December 2017. The literature search identified 1031 potentially relevant studies, and after the deletion of duplicates and excluded papers, 98 full-text articles were screened. A total of 39 cases were reviewed from 32 studies in the data extraction. The average age at the time of laryngeal synovial sarcoma diagnosis was 32 years (range, 11-79 years). In all cases (n = 39), patients underwent wide surgical excision, with 20 patients requiring a partial or total laryngectomy. A total of 18 patients received adjuvant and 3 received neoadjuvant radiotherapy. Chemotherapy was used in 10 cases, with ifosfamide the most frequently used agent. There was considerable variability in the order and combinations of the abovementioned treatments. No clinicopathologic factors or treatment regimens were associated with improved overall survival or lower rate of recurrence. There is a paucity of literature and heterogeneity in clinical approaches to this highly aggressive sarcoma. Reporting of cases must be standardized and formal guidelines must be established to guide clinical management. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.
- Author
-
Janoray, Guillaume, Pointreau, Yoann, Alfonsi, Marc, Sire, Christian, Geoffrois, Lionel, de Raucourt, Dominique, Bardet, Etienne, Calais, Marie-Hélène, Garaud, Pascal, and Calais, Gilles
- Subjects
- *
ANTINEOPLASTIC agents , *CANCER chemotherapy , *CISPLATIN , *CONFIDENCE intervals , *FLUOROURACIL , *PATIENT aftercare , *QUALITY of life , *RADIATION doses , *RADIOTHERAPY , *SURVIVAL , *DOCETAXEL , *HYPOPHARYNGEAL cancer , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics ,LARYNGEAL tumors - Abstract
In Europe, induction chemotherapy (ICT) followed by radiotherapy is preferred to conventional chemoradiotherapy to avoid total laryngectomy in patients with laryngeal/hypopharyngeal cancer. In comparison with conventional radiotherapy, bioradiotherapy with cetuximab significantly improves locoregional control rates (LCRs) and overall survival (OS) without any increase in unmanageable toxicity. Patients included had untreated non-metastatic stage III–IV laryngeal/hypopharyngeal invasive squamous cell carcinoma. Good responders after three cycles of docetaxel-cisplatin-5-fluorouracil (TPF)-ICT (docetaxel and cisplatin, 75 mg/m2 each on day 1, and 5-fluorouracil, 750 mg/m2/day on days 1–5) every 3 weeks were randomised to receive radiotherapy (70 Gy) with concurrent cisplatin (100 mg/m2/day on days 1, 22 and 43 of radiotherapy) or cetuximab (400 mg/m2 of loading dose, 250 mg/m2/week during radiotherapy). The primary end-point was larynx preservation. The secondary end-points were laryngo-oesophageal dysfunction-free survival (LEDFS), LCR and OS. A total of 153 patients were enrolled. Among 126 TPF-ICT responders, 116 were randomised to receive either cisplatin (n = 60) or cetuximab (n = 56). The median follow-up was 77.5 months. Five-year OS rates were 66.6% (95% confidence interval [CI]: 0.54–0.79) versus 66.9% (95% CI: 0.54–0.79) (p = 0.9), respectively. Five-year LCRs were 79.8% (95% CI: 69.5–90.0) versus 67.8% (95% CI: 55.1–80.5%) (p = 0.18). Five-year LEDFS was 62.2% (95% CI: 49.7–74.8%) versus 56.2% (95% CI: 43.0–69.4) (p = 0.38). Late grade III/IV salivary gland and laryngeal toxicity occurred in 10.3% versus 9.8% and 6.8% versus 11.8% of patients receiving cisplatin-radiotherapy versus cetuximab, respectively. No significant difference in LEDFS was observed between the two arms. TPF-ICT followed by conventional chemoradiotherapy or cetuximab was feasible, and long-term toxicity was not statistically different between the two arms. LEDFS appears as a relevant end-point. • This is the first prospective evaluation of LODFS. • Cisplatin and cetuximab concomitant to radiotherapy after ICT are efficient in terms of LODFS. • LODFS is more relevant than larynx preservation criteria. • At five years, no unexpected toxicities were reported. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Small Cell Carcinoma in the Head and Neck.
- Author
-
Wakasaki, Takahiro, Yasumatsu, Ryuji, Masuda, Muneyuki, Matsuo, Mioko, Tamae, Akihiro, Kubo, Kazuhiko, Kogo, Ryunosuke, Uchi, Ryutaro, Taura, Masahiko, and Nakagawa, Takashi
- Subjects
- *
CANCER chemotherapy , *HEAD tumors , *METASTASIS , *NECK tumors , *HEALTH outcome assessment , *PARANASAL sinus cancer , *RADIOTHERAPY , *SALIVARY gland tumors , *SURVIVAL , *TIME , *TUMOR classification , *HYPOPHARYNGEAL cancer , *SMALL cell carcinoma , *OROPHARYNGEAL cancer , *CHEMORADIOTHERAPY ,LARYNGEAL tumors ,NASOPHARYNX tumors - Abstract
Objectives: Small cell carcinomas in extrapulmonary sites (ESmCCs) are very rare. ESmCCs originating in the head and neck account for approximately 10% of all ESmCCs, and there are few reports about this disease. ESmCCs have an aggressive natural history characterized by widespread metastasis. The aim of this study was to investigate the characteristics and outcomes of patients with ESmCCs of the head and neck. Methods: The outcomes of 21 patients with ESmCCs of the head and neck treated between January 2001 and December 2015 at the authors' hospital and associated facilities were reviewed. Results: There were 18 men and 3 women, and the median age was 74 years (range, 53-91 years). The tumor site was the larynx in 6 patients; the paranasal sinus in 5; the hypopharynx in 3; the oropharynx in 2; the nasopharynx in 2; and the oral cavity, salivary gland, and primary unknown in 1 patient each. The extent of the disease was staged as follows: stage I or II, 3 cases; stage III, 4 cases; stage IVA, 9 cases; stage IVB, 1 case; and stage IVC, 4 cases. The median observation time was 17 months (range, 1-103 months). Four patients (19%) had distant metastasis at initial treatment, and 13 patients (62%) developed distant metastasis within 3 years. Treatments were administered, including radical surgery (9 patients), radiation therapy (5 patients), chemoradiotherapy (7 patients), and chemotherapy (6 patients). The 1- and 3-year overall survival rates of patients were 56% and 37%, respectively. More than half of the patients died of distant metastasis. Conclusions: ESmCCs of the head and neck have a poor prognosis, similar to those of carcinomas in many other sites. Control of distant metastasis would contribute to improving the prognosis of ESmCCs of the head and neck. Further studies are required for better understanding these disease entities and their response to treatment modalities. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. A Supraglottic Mass in a Pediatric Patient: An Unusual Presentation of Lymphoma.
- Author
-
Perez, Paloma Irizarry, McIlwain, Wesley, Winters, James, Dhesi, Mary, and Rogers, Derek J.
- Subjects
- *
DOXORUBICIN , *LYMPHOMA diagnosis , *VINCRISTINE , *PREDNISONE , *CYCLOPHOSPHAMIDE , *B cell lymphoma , *BIOPSY , *CANCER chemotherapy , *COMPUTED tomography , *HYPOPHARYNX , *LYMPHOMAS , *NECK , *PEDIATRICS , *SURVIVAL , *SYMPTOMS , *THERAPEUTICS ,LARYNGEAL tumors - Abstract
Objective: To present a case of laryngeal lymphoma in a pediatric patient and perform a literature review of this rare entity. Patient: A 13-year-old male presented with a rapidly enlarging right neck mass. Work-up of the neck mass included a computed tomography scan of the neck with contrast and revealed a 2.5 cm right level II neck mass and an asymmetric lobulated soft tissue mass in the right pyriform sinus. Intervention: The patient underwent excisional biopsy of the right supraglottic mass. Once his diagnosis was confirmed, he was treated with a standard lymphoma protocol. Results: Intraoperative frozen analysis revealed a small blue cell tumor. Final pathology demonstrated diffuse large B-cell lymphoma of the germinal center B-cell subtype (GC-DLBCL). The patient underwent treatment with primary chemotherapy 12 days after his original procedure with cyclophosphamide, doxorubicin, vincristine, and prednisone. Conclusion: Laryngeal lymphoma remains extremely rare in the pediatric population. With appropriate treatment, the 5-year disease-free survival remains excellent for germinal center diffuse large B-cell lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Clinical Utility of Pretreatment and 3-Month 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography Standardized Uptake Value in Predicting and Assessing Recurrence in T3-T4 Laryngeal Carcinoma Treated With Definitive Radiation.
- Author
-
Mayo, Zachary, Seyedin, Steven N., Mallak, Nadine, Mott, Sarah L., Menda, Yusuf, Graham, Michael, and Anderson, Carryn
- Subjects
- *
CANCER chemotherapy , *CANCER patients , *CANCER relapse , *COMPUTED tomography , *DEOXY sugars , *PATIENT aftercare , *RADIOPHARMACEUTICALS , *SQUAMOUS cell carcinoma , *STATISTICS , *SURVIVAL , *POSITRON emission tomography , *TOBACCO products , *DESCRIPTIVE statistics ,LARYNGEAL tumors - Abstract
Objectives: The aim of this study was to investigate the utility of pretreatment and 3-month 18F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) standardized uptake value (SUV) in predicting and assessing recurrence in T3-T4 laryngeal carcinoma treated with definitive radiation therapy (RT). Methods: Patients with newly diagnosed T3-T4 laryngeal squamous cell carcinoma treated with definitive RT from 2004 to 2014 were reviewed. Patients who underwent pretreatment or 3-month PET/CT 2 to 4 months after treatment were included. Those with prior systemic, surgical, or RT treatment were excluded. The primary objective was to assess whether pretreatment or posttreatment maximum SUV of the primary site (pSUV) of disease was associated with local recurrence-free survival. Overall survival was a secondary end point. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated to assess the accuracy of 3-month PET/CT at the larynx primary. Results: Twenty-eight patients were eligible for analysis. Median follow-up time was 34.7 months (range, 5.3-138.7 months), and median age was 57 years. Most patients had supraglottic (71.4%), T3 (89.3%), N2 (50.0%) disease, received chemotherapy (96.4%), and had histories of tobacco use (96.4%). On univariate analysis, 3-month posttreatment pSUV was associated with local recurrence-free survival (P < .01), while pretreatment pSUV was not (P = .41). No other associations were found with local recurrence-free survival. Neither pretreatment nor 3-month pSUV was significantly associated with overall survival. The calculated sensitivity, specificity, positive predictive value, and negative predictive value of 3-month PET/CT at the primary site were 33%, 85%, 40%, and 81%, respectively. Conclusions: High initial fluorodeoxyglucose uptake in T3-T4 laryngeal primaries did not show an association with the risk for postradiation local relapse or overall survival, while increased fluorodeoxyglucose uptake at 3 months was associated with increased local recurrence. At 3 months, the relatively low sensitivity and positive predictive value may limit the utility of PET/CT in the assessment of persistent advanced laryngeal cancer after definitive radiation. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Radiotherapy for Elderly Patients Diagnosed with Laryngeal Carcinoma: A Single Center Experience.
- Author
-
SERT, Fatma, ÖZTÜRK, Kerem, and ESASSOLAK, Mustafa
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *BLOOD diseases , *ADJUVANT treatment of cancer , *CANCER chemotherapy , *CANCER relapse , *CISPLATIN , *LYMPH nodes , *MEDICAL protocols , *METASTASIS , *POSTOPERATIVE period , *RADIATION doses , *RADIATION injuries , *RADIOTHERAPY , *SURVIVAL , *TUMOR classification , *TREATMENT effectiveness , *RETROSPECTIVE studies , *CHEMORADIOTHERAPY , *OLD age , *PROGNOSIS , *DIAGNOSIS , *TUMOR treatment ,LARYNGEAL tumors - Abstract
OBJECTIVE To evaluate the efficacy and toxicity of definitive and postoperative radiotherapy (RT) for laryngeal carcinoma patients aged ≥70 years. METHODS Data of patients between December 2006 and January 2016 were retrospectively analyzed. In total, 66 (4 females and 62 males) patients were evaluated for this analysis. The median age was 74 (range, 70-86 years) years. The total RT dose was 70 Gy and 60-66 Gy for definitive and postoperative settings with 2 Gy per fraction, respectively. RESULTS The median follow-up time was 29.5 (range, 4-126 months) months. Using the tumor, node, metastasis (TNM) classification, tumors were stage IIA (18.2%), stage IIIA (31.8%), stage IIIB (3%), and stage IVA (47%). The purpose of RT was definitive for 33 (50%) patients and postoperative for 33 (50%) patients. Concomitant chemotherapy was used in 21 (31%) patients with 9 (42%) receiving cetuximab and 12 (58%) receiving cisplatin. Cisplatin dose reduction was needed in 20% patients, but cetuximab was used as per a suggested protocol. The 3-year local relapse free (LRF), metastases free (MF), and overall survival rates for all patients were 74%, 84%, and 48%, respectively. Only 26 (40%) patients died due to disease specific problems, and 18 (27%) patients died of unknown causes. In the toxicity evaluation, no grade 3-4 adverse effect was seen. Any type of cytopenia status was reported in 14 (21%) patients, and this rate was statistically higher in concomitant radiochemotherapy group (p=003). CONCLUSION RT seems to be an effective therapy in elderly population either alone or concomitant with chemotherapy in definitive and postoperative settings. In contrast, comorbid diseases should be managed carefully in the treatment and follow-up periods. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
20. Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer.
- Author
-
Liu, Shuzhou, Fang, Jugao, Ma, Hongzhi, Meng, Lingzhao, Bai, Yunfei, Feng, Ling, Lian, Meng, Li, Pingdong, Zhong, Qi, and Hou, Lizhen
- Subjects
- *
METASTASIS , *ANTINEOPLASTIC agents , *CANCER chemotherapy , *CHINESE people , *CISPLATIN , *CONFIDENCE intervals , *FLUOROURACIL , *LARYNGECTOMY , *LARYNX , *SURVIVAL , *DECISION making in clinical medicine , *HYPOPHARYNX , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *PREVENTION , *TUMORS ,LARYNGEAL tumors - Abstract
Backgroud: Induction chemotherapy, as a larynx preservation treatment, has been available for over 20 years. We conducted a retrospective study to evaluate the efficacy of this protocol with taxene, cisplatin and 5-fluorouracil in Chinese patients with hypopharyngeal cancer that chose preservation strategy. Material and methods: 170 patients with locally advanced hypopharyngeal cancer were assigned to receive induction chemotherapy. 107 patients (63%) with complete response or partial response received larynx preservation treatment and 63 non-responders (37%) received radical surgery. Results: Median survival time was 30 months (range: 3-59 months). 63 patients (37%) had local-regional failure and 15 (9%) had distant metastasis. Three-year LFS was 27.8% (95% CI: 23.6-32.0%). The estimated three-year overall survival rate was 44.5% (95% CI: 39.5-49.5%). There was no significant difference in the three-year survival rate between responders (44.8%) and non-responders (43.9%) (p = .237), however patients with a partial response had a significant decrease in survival (32.2%) (p < .001). Conclusions: In patients with hypopharyngeal cancer, ICT with TPF regimen followed by RT, as a larynx preservation treatment, may be suitable for complete responders, but not partial responders. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Recurrent bacterial translocation from gut and sepsis in Head and neck cancer patients and its prevention by probiotics.
- Author
-
Gunduz, Mehmet, Murakami, Daichi, Gunduz, Ihsan, Tamagawa, Shunji, Hiraoka, Masanobu, Sugita, Gen, and Hotomi, Muneki
- Subjects
THERAPEUTIC use of probiotics ,HEAD & neck cancer ,GUT microbiome ,CANCER chemotherapy ,HYPOPHARYNGEAL cancer ,PREVENTION ,CANCER treatment ,ANTINEOPLASTIC agents ,BACTERIAL physiology ,BIFIDOBACTERIUM ,INTESTINAL mucosa ,HEAD tumors ,LACTOBACILLUS ,LARYNGEAL tumors ,NECK tumors ,SEPSIS ,SQUAMOUS cell carcinoma ,DISEASE complications ,PHARMACODYNAMICS ,TUMOR treatment - Abstract
Head and neck cancers are the 6th most common cancer type in human malignant tumors and treated with chemoradiotherapy and surgery. Chemotherapy during these treatment modalities leads to damage of intestinal epithelial barriers and results in translocation of intestinal bacteria in bloodstream through invasion in these damaged regions. In this report, we report two cases of hypopharyngeal cancer patients, both of whom received chemotherapy before surgery. The patients demonstrated repeated sepsis before and after surgery, supporting translocation of intestinal bacteria. Proper continuous probiotic use prevented proliferation and intestinal bacterial translocation. Hypothesis of bacterial translocation and prevention by probiotics are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Human papillomavirus infection in patients with laryngeal carcinoma.
- Author
-
Onerci Celebi, Ozlem, Sener, Ebru, Hosal, Sefik, Cengiz, Mustafa, Gullu, Ibrahim, and Guler Tezel, Gaye
- Subjects
- *
LARYNGEAL cancer , *PAPILLOMAVIRUSES , *IN situ hybridization , *GENOTYPES , *CANCER chemotherapy , *PAPILLOMAVIRUS disease diagnosis , *LONGITUDINAL method , *PAPILLOMAVIRUS diseases , *DIAGNOSIS ,LARYNGEAL tumors - Abstract
Background: The aim of this study was to determine the HPV positivity rate in patients with laryngeal cancer, and to determine the effect of HPV positivity on survival. An additional aim was to determine if patients with HPV positive laryngeal cancer are more sensitive to chemotherapy and if such sensitivity differs according to chemotherapy protocol.Methods: The study included laryngeal specimens obtained from 82 laryngeal cancer patients and 11 laryngeal specimens with normal laryngeal mucosa that were obtained from our hospital's paraffin block archives between 1995 and 2013. HPV was detected via chromogenic in situ hybridization (cISH) and confirmed via genotyping.Results: HPV was not detected in any of the 82 laryngeal cancer patients' laryngeal specimens, nor in any of the 11 archived laryngeal specimens with normal laryngeal mucosa via cISH. Genotyping confirmed these findings; none of the HPV types studied were detected in any of the specimens. As none of the study samples were HPV positive, it was not possible to compare survival, recurrence, or chemotherapy sensitivity.Conclusions: HPV infection is not a leading cause of laryngeal cancer; however, additional research on HPV positivity in patients with laryngeal cancer and its effect on recurrence, survival, and chemotherapy sensitivity is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
23. Primary non-Hodgkin's lymphoma of the larynx.
- Author
-
Nerurkar, N and Sarkar, A
- Subjects
- *
GLOTTIS , *IMMUNOHISTOCHEMISTRY , *CANCER chemotherapy , *TREATMENT delay (Medicine) , *POSITRON emission tomography , *LARYNGOSCOPY , *COMPUTED tomography , *COVID-19 pandemic , *IMMUNOTHERAPY ,LARYNGEAL tumors - Abstract
The article describes the case of a patient with primary non-Hodgkin's lymphoma (NHL) of the larynx. Topics discussed include characterization of primary NHL, the symptoms experienced by the patient, results of the patient's laboratory tests, treatments given to the patient, and anesthetic management prior to surgery of the patient.
- Published
- 2022
- Full Text
- View/download PDF
24. Leiomyosarcoma of the Larynx: A Complex Diagnosis.
- Author
-
Molteni, Gabriele, Soloperto, Davide, Fabbris, Cristoforo, Gazzini, Luca, De Rossi, Stefano, Valotto, Giovanni, and Marchioni, Daniele
- Subjects
- *
CANCER chemotherapy , *CANCER relapse , *CARTILAGE , *COMPUTED tomography , *LARYNGOSCOPY , *LARYNX , *PALLIATIVE treatment , *TRACHEAL cartilage , *LEIOMYOSARCOMA ,LARYNGEAL tumors - Abstract
The article presents a case report of an 84-year-old man with dysphonia and a polypoid lesion of the right true vocal fold with normal motility. Following 2 surgeries, he had thickening of the right laryngeal wall with wide fluid collection and underwent debridement of the necrotic tissue and purulent collection drainage, and a laryngectomy which showed transglottic extenstion of the ulcerated material consistent with leiomyosarcoma. The patient's condition improved, and oral feeding started.
- Published
- 2020
- Full Text
- View/download PDF
25. Curative effect of chemotherapy, KTP lasers, and CO2 lasers combined with chemotherapy in the treatment of adult laryngeal hemangioma.
- Author
-
Wu, Xiufa, Mao, Wenjing, He, Peijie, and Wei, Chunsheng
- Subjects
- *
ANTINEOPLASTIC antibiotics , *ANALYSIS of variance , *CANCER chemotherapy , *COMBINED modality therapy , *LARYNGOSCOPY , *HEMANGIOMAS , *MEDICAL lasers , *LOGISTIC regression analysis , *TREATMENT effectiveness , *RETROSPECTIVE studies , *KRUSKAL-Wallis Test , *ADULTS , *PROGNOSIS , *DIAGNOSIS , *TUMOR treatment , *THERAPEUTICS ,LARYNGEAL tumors - Abstract
Purpose: To evaluate three methods for treating adult laryngeal hemangiomas: conventional chemotherapy, CO2 laser combined with chemotherapy, and KTP laser. And to identify risk factors that affected the prognosis of the lesions. Method: A retrospective analysis was performed on the data from patients with adult laryngeal hemangiomas treated by one of three aforementioned methods, the curative efficacy, and safety of those methods was compared. Results: All cases were confirmed by suspension micro-laryngoscope examination. Pre- and post-treatment clinical photographs were taken and the outcomes were graded. Thirty-eight patients in 48 different cases were enrolled in the study between June 2010 and June 2016, and some patients were treated more than once. The treatment efficacy of the KTP laser was higher than that of chemotherapy according to the Kruskal-Wallis ANOVA test; however, the ordinal logistic regression showed that the choice of surgical procedure did not affect the treatment results; only the size of the bases of the lesions affected the prognosis of adult laryngeal hemangiomas. Conclusions: Pingyangmycin injection, KTP laser, and CO2 laser combined with chemotherapy are safe and effective methods for the treatment of adult laryngeal hemangiomas. The size of base of the lesion affects the prognosis of the hemangiomas. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Outcome of carotid and subclavian blowout syndrome in patients with pharynx- and larynx carcinoma passing a standardized multidisciplinary treatment.
- Author
-
Gahleitner, Constanze, Hofauer, Benedikt, Storck, Katharina, and Knopf, Andreas
- Subjects
- *
HEMORRHAGE prevention , *CANCER chemotherapy , *FISTULA , *HEAD tumors , *HEALTH care teams , *EVALUATION of medical care , *MEDICAL emergencies , *NECK tumors , *SUBCLAVIAN artery , *WOUND care , *CAROTID artery dissections , *DISEASE complications , *DIAGNOSIS ,PHARYNX tumors ,LARYNGEAL tumors - Abstract
Background: Carotid blowout syndrome (CBS) is one of the most feared emergencies in the head and neck surgery and tends to occur in patients with head and neck cancer, wound complications, pharyngocutaneous fistulas, or after radio(chemo)therapy. CBS is always life threatening and associated with a 50% mortality/morbidity rate.Methods: Between 2007 and 2015, a total of 51 patients who developed CBS caused by the tumour masses or after radio(chemo)therapy were included. All patients underwent a standardised bleeding management.Results: In 86% of patients, CBS was associated with manifest carcinoma. Fifty three percent of patients were treated by transcervical surgery, in 36% of these cases surgery was supplemented by endovascular approaches. Severe complications such as re-bleeding or cerebral ischemia occurred infrequently. Seven patients died because of the acute bleeding.Conclusion: CBS associated with head and neck cancer carries poor mid and long-term prognoses. An interdisciplinary standardised treatment path dramatically reduced overall morbidity and mortality. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
27. Voice and swallowing after total laryngectomy.
- Author
-
Arenaz Búa, Beatriz, Pendleton, Hillevi, Westin, Ulla, and Rydell, Roland
- Subjects
- *
PHARYNX , *AGE distribution , *ARTIFICIAL larynges , *CANCER chemotherapy , *CANCER patients , *DEGLUTITION , *ESOPHAGUS , *LARYNGECTOMY , *QUESTIONNAIRES , *RADIOTHERAPY , *TUMOR classification , *HUMAN voice , *DATA analysis software , *DISEASE complications , *ANATOMY ,LARYNGEAL tumors - Abstract
Background: Voice and swallowing problems are often seen in patients with advanced larynx cancer, after total laryngectomy (TL) and chemo/radiotherapy. The aim of this study was to determine the occurrence of voice and swallowing problems in patients who have been laryngectomised and investigate if these symptoms were related to age, time after TL, radiotherapy and TNM-classification. In addition, we studied how often the patients changed their voice prostheses and the need of therapeutic interventions after TL. Methods: Forty-five patients were included in the study and completed the Swedish version of the Sydney Swallow Questionnaire and the Voice Handicap Index-T. Results: Swallowing problems were reported by 89% of the patients and moderate-to-severe voice handicap was reported by 66%. Most of the subjects who had dysphagia also presented voice problems (rs=0.67 p≤.01). Additional therapeutic interventions to manage problems with voice and/or swallowing after TL were required in 62% of the patients. Conclusions: Swallowing and voice problems after TL are common. Thus, the preoperative information and assessment of these functions, as well as the treatment and the post-operative rehabilitation should be evaluated and optimised to provide better functional results after treatment of advanced larynx cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
28. Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3Mo pyriform sinus carcinoma.
- Author
-
Anniko, Matti
- Subjects
- *
CANCER prognosis , *CANCER treatment , *CISPLATIN , *FLUOROURACIL , *NECK tumors , *CANCER chemotherapy , *HEAD tumors , *HYPOPHARYNX , *CHEMORADIOTHERAPY , *SURGERY , *TUMOR treatment ,LARYNGEAL tumors - Abstract
The article discusses the surgical treatment of head and neck cancers which requires an ever increasing resources for in-patients in hospitals. It states that surgery followed by radiotherapy and chemotherapy in various combinations offers optimal prospects of survival and whenever possible, to preserve organs even in advanced cases.
- Published
- 2018
- Full Text
- View/download PDF
29. Effects of the Akt inhibitor Src-homology 5 on proliferation and apoptosis of the laryngeal squamous cell carcinoma.
- Author
-
Jia, Tao, Cao, Qing-Qing, Chen, Xue-Mei, and Xu, Feng-Lei
- Subjects
- *
SQUAMOUS cell carcinoma , *CANCER treatment , *CELL proliferation , *RADIOTHERAPY , *LARYNGECTOMY , *CANCER chemotherapy , *PATIENTS , *APOPTOSIS , *CELL lines , *CELL physiology , *INOSITOL phosphates , *TRANSFERASES ,LARYNGEAL tumors - Abstract
Objective: The aim of this study was to investigate the effect of the Akt inhibitor Src-homology 5 (SH-5) on the proliferation and apoptosis of laryngeal squamous cell carcinoma cells (LSCC; Hep-2 cells) and to elucidate the possible mechanisms of such effects.Materials and Methods: Hep-2 cells were treated with different concentrations of the Akt inhibitor SH-5. The inhibitory effect of SH-5 on cell proliferation was examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, whereas apoptosis was detected by flow cytometric based on Annexin V/propidium iodide (PI) staining. In addition, the expression level of Akt protein was evaluated by Western blot analysis.Results: MTT assay results revealed that SH-5 inhibited the proliferation of Hep-2 cells, with its greatest effect being observed at 2 μM. Apoptosis of Hep-2 cells increased following treatment with SH-5. Treatment of Hep-2 cells with SH-5 decreased the expression of Akt, and this effect was statistically significantly when compared with that in controls (P < 0.05).Conclusion: SH-5 inhibited proliferation and induced apoptosis in the LSCC cell line Hep-2. These effects may be caused by inhibition of the phosphoinositide 3-kinase-Akt signaling pathway. We believe that our data will provide useful insights into LSCC target treatment and future researchn. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
30. Leukocytoclastic vasculitis complicating cisplatin + radiation treatment for laryngeal cancer: a case report.
- Author
-
Quintanilha, Júlia Coelho França, Visacri, Marília Berlofa, Amaral, Laís Sampaio, Lima, Carmen Silvia Passos, Cintra, Maria Letícia, and Moriel, Patricia
- Subjects
- *
LEUKOCYTOCLASTIC vasculitis , *CISPLATIN , *CANCER radiotherapy , *LARYNGEAL cancer treatment , *CANCER chemotherapy , *IMMUNE complexes , *ANTINEOPLASTIC agents , *LEG , *SKIN , *VASCULITIS , *DISEASE complications ,LARYNGEAL tumors - Abstract
Background: Leukocytoclastic vasculitis is typically mediated by deposition of immune complexes and is related to many causes, including medication. To the best of our knowledge, leukocytoclastic vasculitis related to cisplatin has not yet been described in the scientific literature.Case Presentation: We report a rare case of leukocytoclastic vasculitis after the first cycle of high-dose cisplatin chemotherapy in a patient with larynx carcinoma. A 48-year-old Caucasian man with larynx carcinoma received a high-dose of cisplatin monochemotherapy (100 mg/m2 every 21 days), along with 70 Gy of radiotherapy divided into 35 sessions, as a therapeutic schedule. Twelve days after the first chemotherapy administration and after 8 sessions of radiotherapy (total of 16 Gy), the patient presented with acute onset of palpable purpura in the lower limbs. The patient was hospitalized for 10 days, and during this period, he underwent several examinations to rule out infectious, autoimmune, and neoplastic disorders. A skin biopsy showed leukocytoclastic vasculitis with a positive pattern for IgM and C3, as detected through direct immunofluorescence. Twenty-five days after cisplatin administration, the chemotherapy regimen was changed to carboplatin AUC 5, and the episodes of purpura ceased, reinforcing the hypothesis of an adverse reaction to cisplatin.Conclusions: Cisplatin can induce leukocytoclastic vasculitis and clinicians should be aware of this potential effect for better case management and diagnosis. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
31. Pharyngotomy in head and neck squamous cell carcinoma: functional and oncological aspects.
- Author
-
Remmert, Carolin, Mansour, Naglaa, Hofauer, Benedikt, Scherer, Elias Q., Bas, Murat, Bier, Henning, and Knopf, Andreas
- Subjects
- *
MOUTH tumors , *OROPHARYNGEAL cancer , *NECK tumors , *CANCER chemotherapy , *CANCER patients , *FLUOROSCOPY , *HEAD tumors , *MEDICAL care , *ONCOLOGY , *PATIENTS , *PHARYNX surgery , *RADIOTHERAPY , *OPERATIVE surgery , *SURVIVAL , *VIDEO recording , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics , *DIAGNOSIS , *SURGERY ,LARYNGEAL tumors - Abstract
Background: Head and Neck Surgery constantly has to oppose non-invasive organ preservation methods and therefore should be evaluated especially with regard to clinical and functional outcome. We will discuss the role of pharyngotomy in the treatment of HNSCC. Methods: Seventy-three patients with carcinoma of the oral cavity, oro-/hypopharynx and supraglottis underwent lateral/median pharyngotomy. Functional and oncological parameters were retrospectively assessed and set into clinical context. Results: The 5-year recurrence-free-interval (RFI) was significantly higher with surgery and adjuvant radio(chemo)therapy (80%; mean RFI: 92 months) when compared to conservative treatment (68%; mean RFI: 68 months). The 5-year overall-survival (OS) after surgery and conservative treatment was 71% and 54%, respectively. Compared to other surgical techniques (mean RFI: 82 months), pharyngotomy demonstrated a significant higher 5-year RFI (mean RFI: 89 months). Conclusions: Pharyngotomy achieves good exposure and clear resection margins that result in a notably good oncological outcome with a minimum of functional loss. In particular, among UICC IV oropharyngeal HNSCC, pharyngotomy is superior in OS and RFI to conservative methods. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. Ninety Day Mortality After Radical Radiotherapy for Head and Neck Cancer.
- Author
-
Dixon, L., Garcez, K., Lee, L.W., Sykes, A., Slevin, N., and Thomson, D.
- Subjects
- *
CAUSES of death , *AGE distribution , *BODY weight , *CANCER chemotherapy , *COMBINED modality therapy , *HEAD tumors , *HEMOGLOBINS , *LIFE skills , *NECK tumors , *HEALTH outcome assessment , *RADIOTHERAPY , *SQUAMOUS cell carcinoma , *SURVIVAL , *COMORBIDITY , *DESCRIPTIVE statistics , *PSYCHOLOGY ,LARYNGEAL tumors ,PHARYNX tumors - Abstract
Aims Treatment for head and neck cancers using definitive radiotherapy, with or without chemotherapy, is associated with significant acute toxicity. Our aim was to assess 90 day mortality after radical radiotherapy. A further aim was to identify patient, tumour or treatment factors associated with early death after treatment and whether these could be used to predict outcomes. Materials and methods In total, 1116 patients with squamous cell pharyngeal and larynx cancer between January 2011 and December 2015 were included. Patients with T1 larynx cancer were excluded. Patients were treated using radical radiotherapy, with or without chemotherapy. Ninety day mortality was calculated using survival of less than 135 days from the planned start date for radical radiotherapy, to include early deaths during and up to 90 days after treatment. Results Overall, 90 day mortality was 4.7%. Among the subgroup of patients treated with concurrent platinum chemotherapy, the 90 day mortality rate was 0.4%. Overall survival at 1, 3 and 5 years was 84%, 62% and 53%, respectively. Factors associated with a higher risk of early death included performance status > 1, haemoglobin <100 g/l, weight < 60 kg, age > 80 years and presence of multiple comorbidities. Conclusion We report excellent crude overall survival rates among our radically treated cohort of head and neck cancer patients. Several factors were associated with an increased risk of death within 90 days of completion of radical head and neck radiotherapy. Given the potential severe acute effects and the impact on patient quality of life associated with radical head and neck radiotherapy, this information is helpful to inform treatment-related discussions with patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
33. Locally advanced laryngeal cancer. Larynx preservation strategies.
- Author
-
Enăchescu, Ciprian, Pitiu, Corina, Yossi, Sena, Eker, Elife, and Caraivan, Ionela
- Subjects
- *
LARYNGEAL cancer , *LARYNGEAL cancer treatment , *LARYNGEAL surgery , *LARYNX , *CANCER chemotherapy , *CANCER immunotherapy , *CANCER radiotherapy ,LARYNGEAL tumors - Abstract
Larynx preservation in locally advanced laryngeal cancer is intended to obtain cancer control and, if possible, the preservation of laryngeal anatomy and functions (speech, swallowing and airway patency). Eligibility criteria for larynx preservation strategies are medical and surgical. Medical factors include age, performance status, nutrition status and visceral functions. Surgical factors are local factors on which depends tumor resectability and post-treatment larynx functionality. Larynx preservation strategies include radiotherapy as local treatment associated with concomitant or sequential chemotherapy. Concomitant cisplatin-fluorouracil (CDDP-FU or PF) chemoradiation and docetaxel-cisplatin-fluorouracil (TPF) induction chemotherapy followed by radiation therapy increased larynx preservation and are evidence-based validated options. After TFP (docetaxel-CDDP-FU) induction chemotherapy, cetuximab-based immunotherapy with concomitant irradiation showed no superiority to concurrent cisplatin-based chemo-radiotherapy and, consequently, this combination should not be used, except for unfit patients to platinum-based regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2017
34. Impact of combined modality treatment with radiotherapy and S-1 on T2N0 laryngeal cancer: Possible improvement in survival through the prevention of second primary cancer and distant metastasis.
- Author
-
Kitani, Yosuke, Kitani, Yuka, Hatakeyama, Hiromitsu, Kubota, Akira, Furukawa, Madoka, Hori, Yukiko, Nakayama, Yuko, Nonaka, Tetsuo, Mizoguchi, Nobutaka, and Oridate, Nobuhiko
- Subjects
- *
LARYNGEAL cancer treatment , *COMBINED modality therapy , *RADIOTHERAPY , *SURVIVAL analysis (Biometry) , *CANCER chemotherapy , *METASTASIS , *HEAD & neck cancer , *CHEMOPREVENTION , *ANTINEOPLASTIC agents , *FLUOROURACIL , *CANCER treatment , *HETEROCYCLIC compounds , *THERAPEUTIC use of antimetabolites , *SECONDARY primary cancer , *COMBINATION drug therapy , *SQUAMOUS cell carcinoma , *PREVENTION , *TUMOR treatment ,LARYNGEAL tumors - Abstract
Background: In patients with head and neck cancer, the management of second primary cancer (SPC) is particularly important for improving survival because of its high incidence and associated mortality. We evaluated the impact of combination chemotherapy on survival and SPC.Method: We retrospectively analyzed data from 49 patients treated with definitive radiation therapy (RT) for T2N0M0 laryngeal squamous cell carcinoma between 2003 and 2011. Among them, 22 patients received combined modality treatment with radiotherapy and S-1 (RT+CT group).Results: The median follow-up period was 71months (32-111months). A significant difference in overall survival (OS, P<0.01) was observed between the RT+CT group (n=22) and the RT alone group (n=27) though no significant differences were observed in local control and disease specific survival. Univariate analyses showed that an older age (P<0.05) and a higher grade (P<0.05) were associated with OS. Multivariate analysis identified chemotherapy as the most significant predictor of survival (OR, 0.056; 95% CI, 0.008-0.353, P<0.01). A significantly lower incidence of distant metastasis (DM)+SPC (5-year incidence: 5% vs. 19%, P<0.05) and fewer deaths from these causes (1 vs. 8: P<0.05) were observed in the RT+CT group. Multivariate analysis showed that chemotherapy was the most significant factor for the incidence of DM+SPC (OR, 0.074; 95% CI, 0.0065-0.84; P<0.05).Conclusion: The findings of this study suggest the possibility that combined modality treatment with radiotherapy and S-1 improve survival by preventing distant metastasis and second primary cancer. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
35. بررسي ميزان بقاي بيماران مبتلا به سرطان حنجره
- Author
-
احمدجعفري, نرگسقلي زاده, رشيدرمضاني, دكتر هانيهامامي رضوي, and دكتر شمسالملوك نجفي
- Subjects
AGE distribution ,CANCER chemotherapy ,COMBINED modality therapy ,LARYNGEAL tumors ,LONGEVITY ,QUESTIONNAIRES ,RADIOTHERAPY ,SQUAMOUS cell carcinoma ,OPERATIVE surgery ,SURVIVAL analysis (Biometry) ,PROPORTIONAL hazards models ,DATA analysis software ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,TREATMENT delay (Medicine) ,PREVENTION - Abstract
Background and Aims: Cancer is the second most common cause of death in developed countries. The goal of this study was to determine the important epidemiologic factors affecting diagnosis and survival rate of patients with laryngeal SCC, for prevention, control and increase longevity. Materials and Methods: In this study, all the cases recorded at the Center of Cancer Office of the Iran Ministry of Health in Tehran between 2005-2009 were examined. From 513 cases, 279 that their follow-up was possible by phone or postal address were included in the study. Data collection were performed from questionnaire. The data were analyzed by SPSS version 20. The Kaplan Meier survival curves were utilized and, moreover, the corresponding influential factors were examined by using the Cox regression test. Results: The mean age of patients were 61.1 years (SD=10.54). The gender of 92.1% of patients were male. The most widely used method for the treatment was a combination of three methods of surgery, radiation therapy, and chemotherapy. The overall five-year survival rate was 75.7% (SD=0.03). The gender, histological differentiation, and professional delay did not exhibit a statistical correlation with the survival rate (P=0.38, 0.14, 0.52), whereas the age and patient delay had a statistically significant relation with the survival rate (P=0.03, 0.07). Conclusion: The survival rate was lower in older patients. Patient and professional delays were high, which need more attention for improving the quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2017
36. Radical radiotherapy for carcinoma of the larynx in the elderly: Functional and oncological outcomes from a tertiary cancer care center in India.
- Author
-
Subramaniam, Narayana R., Srinivasalu, Vijay Kumar, Balasubramanian, Deepak, Pushpaja, K. U., Nair, Anoop Remesan, Prameela, Chelakkot, Thankappan, Krishnakumar, and Iyer, Subramania
- Subjects
- *
RADIOTHERAPY , *CANCER treatment , *CANCER chemotherapy , *CARCINOMA , *CANCER patient care , *ONCOLOGY , *DIAGNOSIS , *CANCER relapse , *COMBINED modality therapy , *LARYNX , *PROGNOSIS , *RADIATION doses , *SQUAMOUS cell carcinoma , *TUMOR classification , *SPECIALTY hospitals ,LARYNGEAL tumors - Abstract
Introduction: It is estimated that around 10% of all head and neck cancer patients in India are aged over 70 years. Elderly patients are often subjected to palliative or inadequate treatment for head and neck cancers in spite of being candidates for curative intent therapy. In this study we evaluated our use of radical radiotherapy in carcinoma larynx for patients over seventy years of age to determine morbidity, likelihood of completing therapy, functional and oncological outcomes.Materials and Methods: 132 patients of squamous cell carcinoma of the larynx treated between 2005-2015 at Amrita Institute of Medical Sciences, Kochi who were seventy years of age or older were included. The endpoint for analysis was overall survival. Survival curves were generated using Kaplan Meier method and univariable analysis was performed using log rank test.Results: The median age of patients was 77 years (range 70-102). All patients (100%) completed radiotherapy with 6 (5%) requiring treatment breaks. All patients had at least minor (grade I/II) toxicities. Grade III toxicities were seen in 10 (8%) of patients. No grade IV reactions or treatment related deaths occurred. When a univariate analysis was performed for determinants of major toxicities with age range, performance status, smoking, number of co-morbidities or TNM stage, no determinants were statistically significant. 2-year disease free survival for stage I, II, III and IV was 100%, 98%, 80% and 64% respectively, and the 2-year overall survival for all four stages was 100%.Conclusion: Patients over seventy years tolerate radical radiotherapy for treatment of laryngeal cancer. In spite of minor toxicities, all patients completed treatment and had good oncological outcomes. Patients with stage III/IV unfit for concomitant chemotherapy administration treated with radiotherapy alone had a good disease free survival. Curative intent therapy should not be withheld from elderly patients on the basis of age. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
37. Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.
- Author
-
Zumsteg, Zachary S., Kim, Sungjin, David, John M., Yoshida, Emi J., Tighiouart, Mourad, Shiao, Stephen L., Scher, Kevin, Mita, Alain, Sherman, Eric J., Lee, Nancy Y., and Ho, Allen S.
- Subjects
- *
HEAD & neck cancer treatment , *CANCER chemotherapy , *CANCER radiotherapy , *TREATMENT effectiveness , *ONCOLOGIC surgery , *COMPARATIVE studies , *DATABASES , *HEAD tumors , *RESEARCH methodology , *MEDICAL cooperation , *MULTIVARIATE analysis , *NECK tumors , *PROBABILITY theory , *RADIOTHERAPY , *RESEARCH , *SQUAMOUS cell carcinoma , *SURVIVAL , *TUMOR classification , *EVALUATION research , *RETROSPECTIVE studies , *HYPOPHARYNX , *OROPHARYNGEAL cancer , *CANCER treatment , *TUMOR treatment , *TUMORS ,LARYNGEAL tumors - Abstract
Background: Single-modality radiotherapy is considered a standard-of-care option for certain stage III, T1-2N1 head and neck squamous cell carcinomas (HNSCCs). The role of concomitant chemoradiation is not well established because there have been no studies comparing chemoradiation with radiation alone in this population.Methods: This study analyzed patients in the National Cancer Data Base with cT1-2N1M0 invasive squamous cell carcinomas of the oropharynx, larynx, and hypopharynx who were diagnosed between 2004 and 2012 and were undergoing definitive radiation. Patients who were undergoing surgery before radiation with unknown follow-up or for whom either the receipt or timing of chemotherapy was unknown were excluded.Results: In all, 5030 patients with T1-2N1 oropharyngeal, laryngeal, or hypopharyngeal cancer were included. The median follow-up was 56.8 months (95% confidence interval [CI], 55.7-58.6 months). Overall, 68% of the patients received concomitant chemoradiation (CCRT). The use of CCRT significantly increased during the time period of this study from 53% in 2004 to 78% in 2012 (P < .001). CCRT was associated with improved overall survival (OS) in comparison with radiation alone in a multivariate analysis (hazard ratio [HR], 0.80; 95% CI, 0.72-0.88; P < .001). In propensity score-adjusted analyses, CCRT remained significantly associated with improved OS, with 5-year OS rates of 63.5% (95% CI, 60.7%-66.2%) and 55.6% (95% CI, 52.7%-58.4%; P < .001) with CCRT and radiation alone, respectively. Subgroup analyses showed a benefit across the majority of subgroups, including patients with oropharyngeal cancer (HR, 0.74; 95% CI, 0.65-0.85; P < .001).Conclusions: Concomitant chemoradiation is associated with improved survival for patients with T1-2N1 HNSCC. Prospective trials in this population should be pursued. Cancer 2017;123:1555-1565. © 2017 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
38. Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET/CT
- Author
-
Wichmann, Gunnar, Krüger, Anne, Boehm, Andreas, Kolb, Marlen, Hofer, Mathias, Fischer, Milos, Müller, Stefan, Purz, Sandra, Stumpp, Patrick, Sabri, Osama, Dietz, Andreas, and Kluge, Regine
- Subjects
- *
CANCER chemotherapy , *COMBINED modality therapy , *COMPUTED tomography , *TUMOR classification , *HYPOPHARYNX , *TREATMENT effectiveness , *TUMORS ,LARYNGEAL tumors - Abstract
Background Long-term laryngectomy-free (LFS), tumour-specific (TSS) and overall survival (OS) is achieved by non-surgical larynx preservation (LP) only in a proportion of patients with locally advanced laryngeal or hypopharyngeal cancer. A score facilitating decision-making after 1 cycle induction chemotherapy (IC-1) may improve LFS and TSS. Methods Early response to IC-1 with TPF ± cetuximab was assessed in 52 patients using endoscopic tumour staging for selecting total laryngectomy for non-responders with endoscopic tumour surface shrinkage <30% versus induction chemotherapy plus radiotherapy (IC + RT) for responders. Computed tomography (CT)-based volumetry was used to assess volumes of primary tumour, neck nodes and their sum; maximum and mean standardised uptake value (SUV max , SUV mean ) were measured by 18 F-FDG-PET/CT. Baseline and residual values after IC-1 were calculated and correlated with LFS, TSS and OS. Results After IC-1, 39/52 patients (75%) were early responders. Early response predicted complete response to IC + RT ( p = 8.48 × 10 −9 ). Early laryngectomised non-responders and responders with endoscopic tumour surface shrinkage > 70% had best OS. Significant independent predictors for LFS in responders are number of CT-staged suspect positive neck nodes (N+), residual primary tumour volume, residual total tumour volume and the ratio of residual SUV max and SUV mean (resSUV max /resSUV mean ). Our LFS-score combines >2N+, residual primary tumour volume > 20%, residual total tumour volume > 5.6 mL and resSUV max /resSUV mean > 1.51 weighted by their hazard ratio (12, 6, 5 and 4); LFS-score ≤ 16 predicts increased LFS, OS and TSS ( p < 0.05). Conclusion LFS-score ≤ 16 identifies in responders to IC-1 the patients with maximum benefit of non-surgical LP achieving long-term LFS. Even more importantly, a LFS-score > 16 defines patients unsuitable for LP applying the TPF/TP IC + RT protocol. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. Evaluation of gender-specific aspects in quality-of-life in patients with larynx carcinoma.
- Author
-
Tan, Sarah, Duong Dinh, Thien An, and Westhofen, Martin
- Subjects
- *
AGE distribution , *CANCER chemotherapy , *HEALTH status indicators , *LARYNX , *QUALITY of life , *QUESTIONNAIRES , *RADIOTHERAPY , *SEX distribution , *TRACHEOTOMY , *DATA analysis software , *DESCRIPTIVE statistics ,LARYNGEAL tumors - Abstract
Conclusions:The results suggest that gender-specific differences in health-related quality-of-life (HRQoL) exist in patients with larynx carcinoma. In previous studies these differences might have been concealed by predominantly male subject groups. Future studies should consider a gender-specific analysis that suits the patient’s idiosyncrasies associated with laryngeal cancer. Objectives:There is little research concerning gender differences in quality-of-life (QoL) in patients with larynx carcinoma. Since laryngeal cancer is predominantly found in males, most studies examining HRQoL are based on a mainly male subject group. HRQoL needs to be assessed to determine the impact of disease and treatment and to evaluate possible treatment regimes. This study examined gender differences concerning HRQoL in 53 patients using EORTC QLQ-C30, and QLQ-H&N35 questionnaires. Methods:Patients treated with larynx carcinoma were given two questionnaires to assess HRQoL. The questionnaires were analyzed for each sex separately, as well as for the entire population. Results:Female patients report significantly worse HRQoL than males. Age could not be identified as a significant predictor for HRQoL when males and females were analyzed together, and does not significantly predict HRQoL in men. However, age was found to be a significant predictor for HRQoL when only females were analyzed. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
40. Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
- Author
-
Bossi, Paolo, Bergamini, Cristiana, Miceli, Rosalba, Cova, Agata, Orlandi, Ester, Resteghini, Carlo, Locati, Laura, Alfieri, Salvatore, Imbimbo, Martina, Granata, Roberta, Mariani, Luigi, Iacovelli, Nicola Alessandro, Huber, Veronica, Cavallo, Anna, Licitra, Lisa, and Rivoltini, Licia
- Subjects
- *
HEAD & neck cancer treatment , *CYTOKINES , *MUCOSITIS , *CANCER chemotherapy , *RADIOTHERAPY , *ANTINEOPLASTIC agents , *CANCER treatment , *MOUTH tumors , *SQUAMOUS cell carcinoma , *HEAD tumors , *NECK tumors , *HYPOPHARYNX , *OROPHARYNGEAL cancer , *CISPLATIN , *FLUOROURACIL , *HYDROCARBONS , *INTERLEUKIN-1 , *INTERLEUKINS , *LONGITUDINAL method , *PHARMACOKINETICS , *RADIATION doses , *SALIVA , *STOMATITIS , *TIME , *TUMOR necrosis factors , *SEVERITY of illness index , *CARBOPLATIN , *TUMOR treatment , *TUMORS ,LARYNGEAL tumors ,NASOPHARYNX tumors - Abstract
Purpose: We assessed the presence of salivary cytokines, their modulation during chemoradiation therapy (CTRT), and their association with oral mucositis severity in patients with head and neck cancer (HNC).Methods and Materials: The present prospective observational study enrolled 55 patients with locally advanced HNC requiring CTRT. We also studied 10 healthy volunteers and 10 patients with other cancers. The salivary levels of 13 cytokines were analyzed. We constructed a cytokine predictive score of oral mucositis severity.Results: The baseline salivary cytokine levels were not associated with the severity of treatment-induced oral mucositis. The cytokine levels overall increased during treatment, especially in patients with worse mucositis. In particular, on univariable analysis, an increase of interleukin (IL)-1β (area under the curve [AUC] 0.733; P=.009), IL-6 (AUC 0.746; P=.005), and tumor necrosis factor-α (AUC 0.710; P=.005) at the third week of treatment was significantly associated with the development of severe oral mucositis. On multivariable analysis, the predictive score based on the IL-1β and IL-6 changes from baseline to week 3 was an early strong predictor of higher grade oral mucositis.Conclusions: The treatment of HNC patients with concurrent CTRT induces a significant increase in the salivary levels of IL-1β, IL-6, and tumor necrosis factor-α, all positively associated with the severity of mucosal toxicity. A greater increase of IL-1β and IL-6 3 weeks after treatment initiation is predictive of worse oral mucositis, representing a potential tool for the early identification of patients at risk. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
41. Multidisciplinary Care of Laryngeal Cancer.
- Author
-
Salvador-Coloma, Carmen and Cohen, Ezra
- Subjects
- *
ANTINEOPLASTIC agents , *CANCER chemotherapy , *CANCER patients , *COMBINED modality therapy , *GLOTTIS , *HEALTH care teams , *MEDICAL lasers , *TUMOR classification , *TREATMENT effectiveness , *PROGNOSIS , *DIAGNOSIS ,LARYNGEAL tumors - Abstract
Treatment of larynx cancer has changed dramatically over the past several years. Novel modalities of treatment have been introduced as organ preservation has been developed. In addition, new targeted therapies have appeared, and improvements in radiotherapeutic and surgical techniques have been introduced. Thus, a large variety of treatment options is increasing local control rates and overall survival; however, selecting the most appropriate treatment remains a challenging decision. This article focuses on the multidisciplinary care of early-stage and locally advanced larynx cancer and attempts to sum up different approaches. Moreover, it reviews state-of-the-art treatment in larynx preservation, which has been consolidated in recent years. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
42. Estimation of the efficacy of chemo-radiotherapy on tumor regression in the patients with laryngeal cancer via computerized tomography using the Cavalieri method.
- Author
-
Bingol, Fatih, Yoruk, Ozgur, Bingol, Buket Ozel, Erdemci, Burak, Ozkan, Ozalkan, and Mazlumoglu, Muhammet Recai
- Subjects
- *
CANCER chemotherapy , *COMPUTED tomography , *SQUAMOUS cell carcinoma , *T-test (Statistics) , *WEIGHTS & measures , *TREATMENT effectiveness , *PRE-tests & post-tests , *DATA analysis software , *DESCRIPTIVE statistics ,LARYNGEAL tumors - Abstract
Conclusion: Calculating tumor volume using the Cavalieri method in laryngeal tumors before and after treatment may be useful to optimize the treatment and to minimize the side-effects of radiotherapy.Purpose: This study aimed to estimate the pre-treatment and post-treatment tumor volumes of the patients to whom radiotherapy or radio-chemotherapy was applied as a treatment using Cavalieri’s Principle as a stereological method and to assess tumor regression rates in the patients with Laryngeal Squamous Cell Carcinoma (LSCC) statistically.Materials and method: Sixteen patients (eight patients with stage T3 and eight patients with stage T4) diagnosed with LCCC bearing the appropriate characteristics to criteria in the otorhinolaryngology clinic were included. Patients had computerized tomography (CT) scans in the axial plane before treatment and 2 months after the treatment. Pre-treatment and post-treatment tumor volumes on CT images were calculated using Cavalieri’s principle as a stereological method and then compared.Findings: Average tumor volumes in patients with stage T3 before and after treatment were 10.12 ± 3.58 cm3and 1.33 ± 1.74 cm3, respectively (p = 0.008). These volumes were 11.92 ± 4.61 cm3and 2.17 ± 2.34 cm3(p = 0.008) for patients with stage T4, respectively. Post-treatment tumor volumes were statistically reduced compared to pre-treatment volumes in all stages. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
43. Olfaction in chemotherapy for head and neck malignancies.
- Author
-
Haxel, Boris R., Berg, Stephanie, Boessert, Patrick, Mann, Wolf J., and Fruth, Kai
- Subjects
- *
SMELL , *CANCER chemotherapy , *HEAD & neck cancer treatment , *FLUOROURACIL , *SQUAMOUS cell carcinoma , *AGE distribution , *ANTINEOPLASTIC agents , *CISPLATIN , *HEAD tumors , *HYDROCARBONS , *LONGITUDINAL method , *NECK tumors , *SENSORY perception , *SMELL disorders , *SMOKING , *CONTROL groups , *CARBOPLATIN ,LARYNGEAL tumors ,PHARYNX tumors - Abstract
Objective: Systemic chemotherapy for different malignancies occurs alongside various side effects, including reduced sensory function. To date, little is known about the effect of chemotherapeutic agents on olfaction. The aim of this study was to provide new data about changes in sense of smell during chemotherapy among patients with advanced squamous cell carcinomas of the head and neck region.Methods: In a prospective, controlled cohort study of patients undergoing up to three courses of chemotherapy (cis- or carboplatin, 5-fluorouracil and docetaxel), olfaction was evaluated prior to and directly following completing a cycle, as well as 3 weeks later with the beginning of the next cycle. For evaluation of sense of smell, the established Sniffin' Sticks test with a determination of threshold, discrimination and identification (TDI) was used. Thirty-three patients (44-85 years old, 25 men and 8 women) were included in the study. Most malignancies were located in the oropharynx.Results: Among the 28 patients who scored normosmic or hyposmic at the beginning of the study, the mean decrease in TDI-score was 0.72 points (24.0-23.2) in the first cycle, 2.1 points (24.5-22.4) in the second cycle and 0.77 points (24.2-23.4) in the third cycle. The decrease during the second cycle was significant. Age (>55 years) had a significant (negative) influence in the first and the second cycles. Smoking only showed a tendency to decreased TDI-scores in chemotherapy. In-between consecutive cycles an increase in TDI-score was obvious (+1.0 points after the first and +1.5 points after the second cycle).Conclusion: Chemotherapy with cisplatin, 5-fluorouracil and docetaxel significantly affected sense of smell to a small extent. This effect was more pronounced in elderly patients and smokers. This fact must be taken into account as a possible additional negative effect in usually prevailing malnutrition in these patients. Furthermore, no cumulative effect of the administered therapeutic agents on olfaction could be proven during this study and recovery occurred within a 3-week period. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
44. Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives.
- Author
-
Marta, Gustavo Nader, Jr.William, William N., Feher, Olavo, Carvalho, André Lopes, Kowalski, Luiz Paulo, and William, William N Jr
- Subjects
- *
CANCER chemotherapy , *TREATMENT of oral cancer , *ORAL cancer patients , *CANCER radiotherapy , *DATA analysis , *CLINICAL trials , *MOUTH tumors , *TREATMENT effectiveness , *OROPHARYNGEAL cancer ,LARYNGEAL tumors ,PHARYNX tumors - Abstract
There is a lack of data from phase III randomized studies to support an ideal approach for locally advanced oral cavity cancer patients. In general, surgery, radiotherapy and chemotherapy are valid treatment options, and combined approach is usually indicated given poor clinical outcomes with single modality therapy. The aim of this study is to review the current status and future perspectives of induction chemotherapy for locally advanced oral cavity cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
45. Treatment Selection for T3/T4a Laryngeal Cancer.
- Author
-
Timme, David W., Jonnalagadda, Sashikanth, Patel, Raunak, Rao, Krishna, and Robbins, K. Thomas
- Subjects
- *
CANCER chemotherapy , *FACTOR analysis , *STATISTICS , *SURVIVAL analysis (Biometry) , *T-test (Statistics) , *TUMOR classification , *DECISION making in clinical medicine , *DATA analysis , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics ,LARYNGEAL tumors - Abstract
Objective: We report the treatment outcomes, including organ preservation, for patients with locally advanced (T3/T4a) laryngeal cancer receiving both surgical and nonsurgical approaches. We hypothesize that selection of treatment protocols aimed to optimize organ preservation does not compromise survival provided careful selection is done through the process of multidisciplinary treatment planning. Methods: Patients with T3-4a laryngeal squamous cell cancer were evaluated and recommended for primary treatment with total or partial laryngectomy (37 patients) or chemoradiotherapy (34 patients). Treatment outcomes were compared between the 2 cohorts. In addition, the laryngeal preservation rate and laryngoesophageal dysfunction-free survival (LEDFS) were determined for the chemoradiation group. Results: The 5-year overall survival rate for patients with T3 lesions was 41% and 40% for the surgical and nonsurgical groups, respectively, and for T4 lesions it was 54% and 53%, respectively. For the chemoradiation group, the rate of overall laryngeal preservation was 79%. LEDFS at 2 years was 40% for T3 lesions and 33% for T4 lesions. Conclusion: Through careful selection, some patients with locally advanced laryngeal cancer can be offered chemoradiation (organ preservation) without compromising survival. However, the patients selected to receive chemoradiation have a high rate of laryngeal and esophageal dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
46. Re-emergence of Surgery in the Management of Head & Neck Cancer.
- Author
-
Hamilton, David, Khan, Muhammad, O'Hara, James, and Paleri, Vinidh
- Subjects
CANCER chemotherapy ,DEGLUTITION ,DEGLUTITION disorders ,ENDOSCOPIC surgery ,HEAD tumors ,LARYNGEAL tumors ,MEDICAL lasers ,NECK tumors ,QUALITY of life ,RADIOTHERAPY ,SURGICAL robots ,DISEASE incidence ,OROPHARYNGEAL cancer ,TUMOR treatment - Published
- 2015
- Full Text
- View/download PDF
47. Osteosarcoma of the larynx.
- Author
-
Sawicki, Piotr, Każmierczak, Wojciech, Szylberg, Łukasz, and Marszałek, Andrzej
- Subjects
- *
OSTEOSARCOMA , *CANCER chemotherapy , *CANCER radiotherapy , *LARYNGECTOMY , *THERAPEUTICS ,LARYNGEAL tumors - Abstract
Malignant neoplasms of the larynx are divided into epithelial and non-epithelial. Non-epithelial neoplasms include, among others, mesenchymal chondrosarcomas and osteosarcomas. Few cases of laryngeal osteosarcomas described in the literature were usually treated by surgery without the need to use adjuvant radio- or chemotherapy. Few authors propose the initial application of radiotherapy or high-dose chemotherapy. Our study presents a very rare case of a woman treated due to laryngeal osteosarcoma. We have also presented diagnostic difficulties preceding a decision to perform radical surgery. The patient had been eligible for radical surgical treatment, even though there were no features of malignancy in a histopathological examination of the biopsy material. Complete laryngectomy was carried out without the surgery of the cervical lymphatic system. Laryngeal osteosarcoma was diagnosed based on the postoperative histopathological examination using vimentin and Ki67. The patient remains under the care of the Otolaryngology and Laryngological Oncology Department and Oncology Centre in Bydgoszcz. There were no reports on local recurrence or distant metastases during regular check-ups. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. 'The Laryngectomee Guide' in Malaysian Language.
- Author
-
BROOK, Itzhak
- Subjects
- *
LARYNGECTOMY , *CANCER chemotherapy ,LARYNGEAL tumors - Abstract
'The Laryngectomee Guide' (Panduan Pesakit Laringektomi) is available now in Malaysian language. The Guide provides information that can assist laryngectomees and their medical providers about medical, dental and psychological issues. It contains information about side effects of radiation and chemotherapy; methods of speaking; airway, stoma, and voice prosthesis care; eating and swallowing; medical, dental and psychological concerns; respiration; anesthesia; travelling and how to cope with the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: Results of the phase 3 ARCON trial.
- Author
-
Janssens, Geert O., van Bockel, Liselotte W., Doornaert, Patricia A., Bijl, Hendrik P., van den Ende, Piet, de Jong, Martin A., van den Broek, Guido B., Verbist, Berit M., Terhaard, Chris H., Span, Paul N., and Kaanders, Johannes H.
- Subjects
- *
CANCER chemotherapy , *CLINICAL trials , *PROBABILITY theory , *DESCRIPTIVE statistics , *KAPLAN-Meier estimator , *PROGNOSIS ,LARYNGEAL tumors - Abstract
Abstract: Purpose: Retrospective studies indicate that larger tumour volume is a strong prognostic indicator for poor tumour control after (chemo)radiotherapy for laryngeal cancer. The impact of tumour volume on the outcome of patients treated within a prospective study comparing accelerated radiotherapy (AR)±carbogen breathing and nicotinamide (ARCON) was investigated. Methods and materials: Of 345 patients with cT2-4 laryngeal cancer, pre-treatment computed tomography (CT) scans of 270 patients were available for tumour volume calculation. Contouring of the primary tumour and involved lymph nodes was reviewed by one experienced head and neck radiation oncologist. Kaplan–Meier plots were used for analysis of outcome. Results: Of 137 AR and 133 ARCON patients, 57 and 80 versus 56 and 77 patients had glottic and supraglottic tumours, respectively. A correlation between primary tumour volume and T-stage was observed (Rs=.51, P <.01). In both treatment arms no correlation was detected between the primary tumour volume and local control (LC), regional control (RC) and metastasis-free survival (MFS). A strong correlation between total nodal volume and N-stage was found (Rs=.93, P <.01). Both in the AR and ARCON groups total nodal volume was not associated with poorer RC rate. However, based on individual lymph node analyses, nodal control was in favour of ARCON, irrespective of volume (P <.01). Conclusion: Neither primary tumour volume, nor total nodal volume is a prognostic factor for patients with cT2-4 laryngeal cancer treated with accelerated radiotherapy±carbogen breathing and nicotinamide. Additional analyses based on individual nodal volumes demonstrate an excellent regional control rate and a significant benefit of ARCON. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
50. Swallowing outcomes following surgical and non-surgical treatment for advanced laryngeal cancer.
- Author
-
Burnip, E, Owen, S J, Barker, S, and Patterson, J M
- Subjects
- *
ANALYSIS of variance , *CANCER chemotherapy , *DEGLUTITION disorders , *LARYNGECTOMY , *HEALTH outcome assessment , *STATISTICS , *DATA analysis , *TREATMENT effectiveness , *CROSS-sectional method , *DATA analysis software , *DESCRIPTIVE statistics ,LARYNGEAL tumors - Abstract
Background:Treatment for advanced laryngeal cancer includes surgery, and/or chemoradiotherapy or radiotherapy. Each of these treatments results in major changes to the swallowing mechanism. Dysphagia is strongly correlated with poorer quality of life. A good understanding of outcomes is needed for well-informed treatment decisions.Method:This study reports on patients' swallowing outcomes following surgical and non-surgical treatments based on the results of three different swallowing tests. A total of 123 data sets were collected in out-patient clinics across two hospitals in North East England.Results:There were no significant differences between treatment groups for patient-reported swallowing outcomes or swallowing performance. However, patients who had undergone chemoradiotherapy or radiotherapy (with or without laryngectomy) had significantly more diet restrictions than other groups.Conclusion:Long-term dysphagia is a common outcome of treatment for advanced laryngeal cancer. Patients treated with chemoradiotherapy and laryngectomy reported the worst overall outcomes. More longitudinal prospective research with large treatment groups is needed to investigate swallowing outcomes following different treatment methods. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.